Information de reference pour ce titreAccession Number: | 00003628-201738060-00016.
|
Author: | Hara, Tetsuya; Ughi, Giovanni J.; McCarthy, Jason R.; Erdem, S. Sibel; Mauskapf, Adam; Lyon, Samantha C.; Fard, Ali M.; Edelman, Elazer R.; Tearney, Guillermo J.; Jaffer, Farouc A.
|
Institution: | (1)Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA (2)Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA (3)Center for System Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA (4)Massachusetts Institute of Technology, Cambridge, MA, USA
|
Title: | |
Source: | European Heart Journal. 38(6):447-455, February 07, 2017.
|
Abstract: | Aims: Fibrin deposition and absent endothelium characterize unhealed stents that are at heightened risk of stent thrombosis. Optical coherence tomography (OCT) is increasingly used for assessing stent tissue coverage as a measure of healed stents, but cannot precisely identify whether overlying tissue represents physiological neointima. Here we assessed and compared fibrin deposition and persistence on bare metal stent (BMS) and drug-eluting stent (DES) using near-infrared fluorescence (NIRF) molecular imaging in vivo, in combination with simultaneous OCT stent coverage.
Methods and results: Rabbits underwent implantation of one BMS and one DES without overlap in the infrarenal aorta (N = 20 3.5 x 12 mm). At Days 7 and/or 28, intravascular NIRF-OCT was performed following the injection of fibrin-targeted NIRF molecular imaging agent FTP11-CyAm7. Intravascular NIRF-OCT enabled high-resolution imaging of fibrin overlying stent struts in vivo, as validated by histopathology. Compared with BMS, DES showed greater fibrin deposition and fibrin persistence at Days 7 and 28 (P < 0.01 vs. BMS). Notably, for edge stent struts identified as covered by OCT on Day 7, 92.8 +/- 9.5% of DES and 55.8 +/- 23.6% of BMS struts were NIRF fibrin positive (P < 0.001). At Day 28, 18.6 +/- 10.6% (DES) and 5.1 +/- 8.7% (BMS) of OCT-covered struts remained fibrin positive (P < 0.001).
Conclusion: Intravascular NIRF fibrin molecular imaging improves the detection of unhealed stents, using clinically translatable technology that complements OCT. A sizeable percentage of struts deemed covered by OCT are actually covered by fibrin, particularly in DES, and therefore such stents might remain prothrombotic. These findings have implications for the specificity of standalone clinical OCT assessments of stent healing.
(C) Copyright Oxford University Press 2017.
|
Author Keywords: | Stent thrombosis; Fibrin; Molecular imaging; Optical coherence tomography.
|
References: | 1. Claessen BE, Henriques JP, Jaffer FA, Mehran R, Piek JJ, Dangas GD. Stent Thrombosis: a clinical perspective. JACC Cardiovasc Interv 2014;7:1081-1092.
2. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
3. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-2441.
4. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, Investigators DS. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-2166.
5. Murata A, Wallace-Bradley D, Tellez A, Alviar C, Aboodi M, Sheehy A, Coleman L, Perkins L, Nakazawa G, Mintz G, Kaluza GL, Virmani R, Granada JF. Accuracy of optical coherence tomography in the evaluation of neointimal coverage after stent implantation. JACC Cardiovasc Imaging 2010;3:76-84.
6. Nakano M, Vorpahl M, Otsuka F, Taniwaki M, Yazdani SK, Finn AV, Ladich ER, Kolodgie FD, Virmani R. Ex vivo assessment of vascular response to coronary stents by optical frequency domain imaging. JACC Cardiovasc Imaging 2012;5:71-82.
7. Yoo H, Kim JW, Shishkov M, Namati E, Morse T, Shubochkin R, McCarthy JR, Ntziachristos V, Bouma BE, Jaffer FA, Tearney GJ. Intra-arterial catheter for simultaneous microstructural and molecular imaging in vivo. Nat Med 2011;17:1680-1684.
8. McCarthy JR, Patel P, Botnaru I, Haghayeghi P, Weissleder R, Jaffer FA. Multimodal nanoagents for the detection of intravascular thrombi. Bioconjugate Chemistry 2009;20:1251-1255.
9. Ughi GJ, Verjans J, Fard AM, Wang H, Osborn E, Hara T, Mauskapf A, Jaffer FA, Tearney GJ. Dual modality intravascular optical coherence tomography (OCT) and near-infrared fluorescence (NIRF) imaging: a fully automated algorithm for the distance-calibration of NIRF signal intensity for quantitative molecular imaging. Int J Cardiovasc Imaging 2015;31:259-268.
10. Hara T, Bhayana B, Thompson B, Kessinger CW, Khatri A, McCarthy JR, Weissleder R, Lin CP, Tearney GJ, Jaffer FA. Molecular imaging of fibrin deposition in deep vein thrombosis using fibrin-targeted near-infrared fluorescence. JACC Cardiovasc Imaging 2012;5:607-615.
11. Vymazal J, Spuentrup E, Cardenas-Molina G, Wiethoff AJ, Hartmann MG, Caravan P, Parsons EC Jr. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol 2009;44:697-704.
12. Jaffer FA, Verjans JW. Molecular imaging of atherosclerosis: clinical state-of-the-art. Heart 2014;100:1469-1477.
13. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011;123:1400-1409.
14. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-342.
15. Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, Kolodgie FD, Virmani R. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv 2011;4:38-46.
16. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart 2003;89:133-138.
17. Malle C, Tada T, Steigerwald K, Ughi GJ, Schuster T, Nakano M, Massberg S, Jehle J, Guagliumi G, Kastrati A, Virmani R, Byrne RA, Joner M. Tissue characterization after drug-eluting stent implantation using optical coherence tomography. Arterioscler Thromb Vasc Biol 2013;33:1376-1383.
18. Templin C, Meyer M, Muller MF, Djonov V, Hlushchuk R, Dimova I, Flueckiger S, Kronen P, Sidler M, Klein K, Nicholls F, Ghadri JR, Weber K, Paunovic D, Corti R, Hoerstrup SP, Luscher TF, Landmesser U. Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J 2010;31:1792-1801.
19. Adriaenssens T, Ughi GJ, Dubois C, Onsea K, De Cock D, Bennett J, Wiyono S, Vanhaverbeke M, Sinnaeve P, Belmans A, D'Hooge J, Desmet W. Automated detection and quantification of clusters of malapposed and uncovered intracoronary stent struts assessed with optical coherence tomography. Int J Cardiovasc Imaging 2014;30:839-848.
20. Authors/Task Force Members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619.
21. Ughi G, Wang H, Gardecki JA, Gerbaud E, Fard AM, Hamidi E, Jacques-Vacas P, Rosenberg-M, Jaffer FA, Tearney GJ. First-In-Human Dual-Modality OCT and Near-Infrared Autofluorescence Imaging of Coronary Artery Disease. JACC Cardiovascular Imaging (in press).
22. Balakrishnan B, Tzafriri AR, Seifert P, Groothuis A, Rogers C, Edelman ER. Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents. Circulation 2005;111:2958-2965.
|
Language: | English.
|
Document Type: | Basic Science.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0195-668X
|
NLM Journal Code: | em8, 8006263
|
DOI Number: | https://dx.doi.org/10.1093/eurhe...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|